Interstitial Lung Diseases

This page lists the latest material on Interstitial Lung Diseases.

Increase in post-transplant survival and quality of life in pulmonary fibrosis with and without telomere dysfunction L. Planas Cerezales (Hospitalet de Llobregat (Barcelona), Spain), E. Arias-Salgado (Madrid, Spain), C. Berastegui Garcia (Barcelona, Spain), A. Montes Worboys (Hospitalet de Llobregat, Spain), R. Gonzalez Montelongo (Santa Cruz de Tenerife, Spain), J. Lorenzo Salazar (Santa Cruz de Tenerife, Spain), V. Vicens-Zygmunt (Hospitalet de Llobregat, Spain), M. Garcia Moyano (Baracaldo, Spain), J. Dorca (Hospitalet de Llobregat, Spain), C. Flores (Santa Cruz de Tenerife, Spain), R. Perona (Madrid, Spain), A. Román (Barcelona , Spain), M. Molina-Molina (Hospitalet de Llobregat, Spain)
Interstitial lung diseases associated with mutations of poly(A)-specific ribonuclease: a multicentric retrospective cohort study Q. Philippot (Paris, France), C. Kannengiesser (Paris, France), I. Ba (Paris, France), A. Gondouin (Besançon, France), J. Naccache (Paris, France), M. Reynaud-Gobert (Marseille, France), Y. Uzunhan (Avicenne, France), B. Bondue (Bruxelles, Belgium), D. Israel Biet (Paris, France), E. Manali (Athens, Greece), S. Papiris (Athens, Greece), L. Wemeau (Lille, France), S. Hirschi (Strasbourg, France), H. Mal (Paris, France), H. Nunes (Avicenne, France), F. Schlemmer (Créteil , France), M. Rigaud (Bordeaux, France), V. Cottin (Lyon, France), B. Crestani (Paris, France), R. Borie (Paris, France)
Bronchoalveolar lavage cytokine profile in patients with Pulmonary Langerhans Cell Histiocytosis differs from other interstitial lung diseases D. Castillo Villegas (Barcelona, Spain), S. Barril Farre (Barcelona, Spain), P. Millan Billi (Barcelona, Spain), O. Sibila Vidal (Barcelona, Spain), A. Luque (Madrid, Spain), P. Acebo (Madrid, Spain), S. Hortelano Blanco (Madrid, Spain)
Chronic Hypersensitivity pneumonitis: risks factors and therapeutic options A. Wells (London, United Kingdom)
Microbiome effects on immunity, health and diseases of the lungs K. Antoniou (Heraklion, Greece)
Combined assessment of regional lung function and morphology using a contrast enhanced Dual-Energy CT protocol: Prospective value of functional imaging biomarkers in longitudinal analysis of patients with Interstitial Lung Disease S. Scharm (Hannover, Germany), S. Dettmer (Hannover, Germany), J. Vogel-Claussen (Hannover, Germany), A. Prasse (Hannover, Germany), L. Knudsen (Hannover, Germany), F. Wacker (Hannover, Germany), J. Fuge (Hannover, Germany), H. Shin (Hannover, Germany)
Methotrexate and risk of Lung disease in Rheumatoid Arthritis: A nationwide population-based cohort study from Denmark S. Burhan Shaker (Copenhagen, Denmark), E. Ibfelt (Copenhagen, Denmark), R. Jacobsen (Copenhagen, Denmark), T. Kopp (Copenhagen, Denmark), R. Cordtz (Aalborg, Denmark), A. Jakobsen (Copenhagen, Denmark), N. Seersholm (Copenhagen, Denmark), L. Dreyer (Aalborg, Denmark)
LSC - 2020 - The respiratory microbiome and metabolome in chronic hypersensitivity pneumonitis R. Invernizzi (London, United Kingdom)
Tt anti fibrotiques hors FPI: approche raisonnée / Anti-fibrotic treatments for conditions other than idiopathic pulmonary fibrosis V. Cottin (Lyon, France)
New antifibrotic drugs: will interstitial diseases patients still need lung transplantation? S. Tomassetti (Florence, Italy)
Genetic findings in patients with different forms of pulmonary hypertension C. Eichstaedt (Heidelberg, Germany), Z. Saßmannshausen (Heidelberg, Germany), H. Gall (Gießen, Germany), A. Ghofrani (Gießen, Germany), H. Seyfarth (Leipzig, Germany), M. Lerche (Leipzig, Germany), M. Halank (Dresden, Germany), P. Xanthouli (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), K. Milger-Kneidinger (Munich, Germany), S. Rosenkrankz (Cologne, Germany), R. Ewert (Greifswald, Germany), M. Lankeit (Berlin, Germany), T. Lange (Regensburg, Germany), K. Hinderhofer (Heidelberg, Germany), E. Grünig (Heidelberg, Germany)
B-cell suppressive therapy and monoclonal antibodies in CTD: does one size fit all? D. Kyburz (Basel, Switzerland)
Fibrotic CTD and interstitial pneumonia with autoimmune features (IPAF): immunosuppressive or/and anti-fibrotic treatment? S. Danoff (Baltimore, United States of America)
Does histology matter in ILD-CTD? V. Poletti (Forlì, Italy)
Presentation of cases by the session facilitator N. Chaudhuri (Manchester (Greater Manchester), United Kingdom)
Pathogenesis of pulmonary fibrosis in sarcoidosis J. Grutters (Nieuwegein, Netherlands)
The effect of high flow oxygen during constant-load cycling test in severe ILD patients. Y. Al Chikhanie (Grenoble, France), F. Hérengt (Dieulefit, France), S. Vergès (Grenoble, France), D. Veale (Dieulefit, France)
Exertional ventilatory and gas exchange inefficiency: contrasting interstitial versus pulmonary vascular disease F. BALZAN (PORTO ALEGRE, Brazil), F. Plachi (PORTO ALEGRE, Brazil), I. Cézar (PORTO ALEGRE, Brazil), L. Cé (PORTO ALEGRE, Brazil), N. Mendes (PORTO ALEGRE, Brazil), K. Käfer (PORTO ALEGRE, Brazil), J. Neder (KINGSTON, Canada), D. Berton (PORTO ALEGRE, Brazil)
Spontaneous resolutive pulmonary necrotizing granulomatosis B. Weicker (Bouge, Belgium), A. Rosoux (Bouge, Belgium), I. Gielen (Gosselies, Belgium), B. Coulier (Bouge, Belgium), R. Frognier (Bouge, Belgium)
High minute volume pulmonary hypertension reversed by thiamine administration in wet Beriberi F. Chertcoff (Ciudad Autónoma Buenos Aires, Argentina), M. Bosio (Ciudad Autónoma Buenos Aires, Argentina), L. Maldonado (Ciudad Autónoma Buenos Aires, Argentina), N. Emery (Ciudad Autónoma Buenos Aires, Argentina), A. Salvado (Ciudad Autónoma Buenos Aires, Argentina)
Altered exhaled NO parameters in newly onset of rheumatoid arthritis M. Högman (Uppsala, Sweden), A. Thornadtsson (Uppsala, Sweden), A. Lind (Gävle, Sweden), T. Weitoft (Gävle, Sweden)
Investigation of granulomatous lung diseases in cases with granulomatosis ocular pathologies T. Cagatay (Istanbul, Turkey), G. Okumus (Istanbul, Turkey), Z. Bingol (Istanbul, Turkey), M. Oray (Istanbul, Turkey), S. Dagistanli (Istanbul, Turkey), Z. Kilicaslan (Istanbul, Turkey), I. Tugal –tutkun (Istanbul, Turkey)
Diffuse Alveolar Hemorrhage: a life-threatening adverse effect of vaping D. Ambrozej (Warsaw, Poland), T. Bielecka (Warsaw, Poland), W. Feleszko (Warsaw, Poland), K. Krenke (Warsaw, Poland)
Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study V. Poletti (Forlì, Italy), C. Albera (Turin, Italy), S. Harari (Milan, Italy), A. Pesci (Monza, Italy), A. Ori (Modena, Italy), G. Crespi (Milan, Italy), B. Campolo (Milan, Italy), C. Vancheri (Catania, Italy)
Association between antifibrotic medications and pneumothorax or pneumomediastinum in patients with idiopathic pulmonary fibrosis T. Akamatsu (Shizuoka, Japan), H. Nakayasu (Shizuoka, Japan), K. Tamura (Shizuoka, Japan), T. Masuda (Shizuoka, Japan), S. Takahashi (Shizuoka, Japan), Y. Tanaka (Shizuoka, Japan), H. Watanabe (Shizuoka, Japan), Y. Kishimoto (Shizuoka, Japan), K. Oishi (Shizuoka, Japan), M. Saigusa (Shizuoka, Japan), A. Yamamoto (Shizuoka, Japan), S. Morita (Shizuoka, Japan), K. Asada (Shizuoka, Japan), T. Shirai (Shizuoka, Japan)
Characteristics and management of patients with idiopathic pulmonary fibrosis treated with pirfenidone capsule or tablet formulation V. Cottin (Lyon, France), S. Guéguen (Paris, France), S. Jouneau (Rennes, France), H. Nunes (Avicenne, France), B. Crestani (Paris, France), P. Bonniaud (Dijon, France), L. Wemeau (Lilles, France), D. Israel-Biet (Paris, France), M. Chevereau (Paris, France), I. Dufaure-Garé (Paris, France), S. Amselem (Paris, France), A. Clément (Paris, France)
Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience A. Stanziola (Napoli (NA), Italy), D. Pentangelo (Napoli (NA), Italy), R. D'Angelo (Napoli (NA), Italy), L. Capitelli (Napoli (NA), Italy), R. Rega (Napoli (NA), Italy), M. Bocchino (Napoli (NA), Italy), U. Malapelle (Napoli (NA), Italy)
Impact of tidal volume, GAP index and anti-fibrotic treatment on disease progression and mortality in IPF patients E. Krauss (Giessen, Germany), B. Ait Ilalne (Paris, France), C. Knittel (Giessen, Germany), J. Wilhelm (Giessen, Germany), R. Dartsch (Giessen, Germany), S. Tello (Giessen, Germany), P. Mahavadi (Giessen, Germany), M. Korfei (Giessen, Germany), W. Seeger (Giessen, Germany), B. Crestani (Paris, France), A. Guenther (Giessen, Germany)
Factors influencing best tolerated dose of pirfenidone (PFD) in patients with IPF N. Agrawal (Mumbai, India), P. Vaidya (Mumbai, India), R. Shah (Mumbai, India), V. Chavhan (Mumbai, India), J. Leuppi (Liestal, Switzerland), A. Leuppi-Taegetmeyer (Liestal, Switzerland), P. Chhajed (Mumbai, India)
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience S. Nayci (Mersin, Turkey), D. Polat (Mersin, Turkey), E. Ozgur (Mersin, Turkey), C. Özge (Mersin, Turkey)
Prevalence of idiopathic pulmonary fibrosis in Japan and the US: a claims-based retrospective study Y. Kondoh (Aichi, Japan), T. Suda (Shizuoka, Japan), Y. Hongo (Tokyo, Japan), M. Yoshida (Tokyo, Japan), S. Hiroi (Tokyo, Japan), K. Iwasaki (Tokyo, Japan), T. Takeshima (Tokyo, Japan), S. Homma (Tokyo, Japan)
Baseline characteristics and survival of patients with idiopathic pulmonary fibrosis (IPF): analysis from the Swedish IPF registry J. Gao (Stockholm, Sweden), D. Kalafatis (Stockholm, Sweden), L. Carlson (Stockholm, Sweden), C. Li (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), M. Sköld (Stockholm, Sweden)
Characteristics and clinical management of IPF patients in Spain: prospective, observational, multicentric study (OASIS study). A. Romero Ortiz (Granada, Spain), M. Rodríguez-Nieto (Madrid, Spain), A. Villar (Barcelona, Spain), E. Cano-Jiménez (Lugo, Spain), A. Ramón (Barcelona, Spain), S. Armengol (Barcelona, Spain), E. Alhaja (Barcelona, Spain), M. Artés (Barcelona, Spain)
Impact of mycophenolate mofetil on lung function in chronic hypersensitivity pneumonitis and connective tissue disease related-ILD E. Soares Seixas (Aveiro, Portugal), P. Serra (Aveiro, Portugal), R. Aguiar (Aveiro, Portugal), M. Ferreira (Aveiro, Portugal), P. Ferreira (Aveiro, Portugal)
Utility of Lung Ultrasound in Interstitial Lung Disease - A Paradigm Shift G. Chawla (Jodhpur, India), N. Dutt (Jodhpur, India), N. Chauhan (Jodhpur, India), R. Niwas (Jodhpur, India), S. Agarwal (New Delhi, India), P. Jain (Jodhpur, India), M. Agarwal (Jodhpur, India)
King’s Brief Interstitial Lung Disease (K-BILD) questionnaire: content relevance in progressive fibrosing ILD (PF-ILD) S. Birring (London, United Kingdom), D. Bushnell (Bethesda, MD, United States of America), K. Cutts (Bethesda, MD, United States of America), M. Baldwin (Ingelheim am Rhein, Germany), K. Rohr (Ingelheim am Rhein, Germany), N. Male (Ingelheim am Rhein, Germany)
Telemetric observation of the course and treatment effects of selected interstitial lung diseases associated with connective tissue diseases (CTD-ILD) – protocol presentation M. Mozga (Lódz, Poland), S. Malysiak-Szponder (Lódz, Poland), J. Milkowska - Dymanowska (Lódz, Poland), A. Bialas (Lódz, Poland), W. Piotrowski (Lódz, Poland)
Relationship between horizontal adductor muscles strength and pulmonary functions in idiopathic pulmonary fibrosis H. Durdu (Giresun, Turkey), S. Yurdalan (Istanbul, Turkey), I. Özmen (Istanbul, Turkey)
The prediction of risk factors of tyrosine kinase inhibitor-induced pneumonitis in non-small cell lung cancer H. Kang (Goyang, Republic of Korea)
Clinico-radiological profile of connective tissue diseases related interstitial lung diseases M. Agarwal (Jodhpur, India), M. Gupta (Jaipur, India), N. Bharti (Jodhpur, India), G. Chawla (Jodhpur, India)
Chest Imaging Abnormalities in Patients with Uncontrolled Rheumatoid Arthritis Prior to Biological Therapy Initiation A. Benjamin (London, United Kingdom), K. Ward (London, United Kingdom)
Hypersentivity pneumonitis in an Interstitial Lung Disease Unit, 5 years’ experience A. Urrutia Gajate (Bilbao (Bizkaia), Spain), A. Rezola Carasusan (Bilbao (Bizkaia), Spain), B. Ortiz De Urbina (Bilbao (Bizkaia), Spain), M. Garcia Moyano (Bilbao (Bizkaia), Spain), R. Zalacain Jorge (Bilbao (Bizkaia), Spain), L. Ruiz Iturriaga (Bilbao (Bizkaia), Spain), L. Serrano Fernandez (Bilbao (Bizkaia), Spain), C. Jaca Michelena (Bilbao (Bizkaia), Spain), B. Gomez Crespo (Bilbao (Bizkaia), Spain)
IMPACT OF IPF PATIENT SUPPORT PROGRAM IN QUALITY OF LIFE M. Molina Molina (Hospitalet de Llobregat, Spain), A. Garcia (Barcelona, Spain), L. Cobo (Barcelona, Spain), C. Ruiz (Barcelona, Spain), K. Portillo (Badalona, Spain), A. Boldova-Loscertales (Zaragoza, Spain), A. Robles-Perez (Mataró, Spain), J. Arribas (Zaragoza, Spain), J. Figuerola (Zaragoza, Spain), R. Blavia (Sant Joan Despi, Spain), Y. Belmonte (Sant Joan Despi, Spain), A. Moreno (Sabadell, Spain), D. Castillo (Barcelona, Spain), A. Villar (Barcelona, Spain), D. Badenes (Barcelona, Spain), E. Balcells (Barcelona, Spain), D. De Zayas (Barcelona, Spain), G. Suarez-Cuartin (Hospitalet de Llobregat, Spain), L. Garcia (Reus, Spain), J. Sellares (Barcelona, Spain), Y. Garcia (Huesca, Spain), S. Barril (Lleida, Spain), J. Sans (Terrassa, Spain), M. Serra (Tortosa, Spain), D. Perich (Manresa, Spain), L. Esteban (Terrassa, Spain), J. Dorca (Hospitalet de Llobregat, Spain), M. Garcia (Barcelona, Spain), P. Cerdá-Cortés (Barcelona, Spain), J. Palma (Hospitalet de Llobregat, Spain)
Dynamics of diagnoses and pharmacotherapy before and after diagnosing idiopathic pulmonary fibrosis J. Rømhild Davidsen (Odense C, Denmark), L. Lund (Odense C, Denmark), C. Laursen (Odense C, Denmark), J. Hallas (Odense C, Denmark), D. Henriksen (Odense C, Denmark)
PREVALENCE AND CHARACTERISTICS OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS ADMITTED FOR PNEUMONIA ACQUIRED IN THE COMMUNITY. I. DOMINGUEZ ZABALETA (Madrid, Spain), J. De Miguel Diez (Madrid, Spain), V. Parra Leon (Madrid, Spain), Z. Ji (Madrid, Spain), A. Lopez De Andres (Madrid, Spain), V. Hernandez Barrera (Madrid, Spain), A. Cerezo Lajas (Madrid, Spain), L. Puente Maestu (Madrid, Spain), R. Jimenez Garcia (Madrid, Spain)
Quantitative CT for the assessment of disease severity in interstitial lung disease D. Parr (Coventry (West Midlands), United Kingdom), E. Helm (Coventry (West Midlands), United Kingdom), J. Shakespeare (Coventry (West Midlands), United Kingdom), R. Hughes (Coventry (West Midlands), United Kingdom), A. Bhalerao (Warwick, United Kingdom)
Eligibility for anti-fibrotic therapy of patients in British Thoracic Society (BTS) UK IPF Registry varies according to the reference values used to calculate FVC P. Molyneaux (London, United Kingdom), M. Loughenbury (London, United Kingdom), S. Welham (London, United Kingdom), J. Hutchinson (Notingham, United Kingdom), H. Adamali (Bristol, United Kingdom), A. Fahim (Wolverhampton, United Kingdom), S. Agnew (Liverpool, United Kingdom), W. Funston (Gateshead, United Kingdom), S. Haney (Ashington, United Kingdom), L. Ho (Oxford, United Kingdom), J. Richardson (London, United Kingdom), H. Almond (Bury St Edmunds, United Kingdom), S. Jones (Bury St Edmunds, United Kingdom), L. Nicol (Edinburgh, United Kingdom), K. Spinks (Lymington, United Kingdom), A. Wilson (Norwich, United Kingdom), L. Spencer (Liverpool, United Kingdom)
Low income and progression free survival in idiopathic pulmonary fibrosis: an association to uncover L. Sese (Bobigny, France), J. Caliez (Bobigny, France), I. Annesi-Maesano (Paris, France), V. Cottin (Lyon, France), G. Pesce (Paris, France), M. Didier (Bobigny, France), Z. Carton (Bobigny, France), D. Israel-Biet (Paris, France), B. Crestani (Paris, France), S. Guillot Dudoret (Rennes, France), J. Cadranel (Paris, France), B. Wallaert (Lille, France), A. Tazi (Paris, France), B. Maître (Créteil, France), G. Prévot (Toulouse, France), S. Marchand-Adam (Tours, France), S. Hirschi (Strasbourg, France), S. Dury (Reims, France), V. Giraud (Boulogne, France), A. Gondouin (Besançon, France), P. Bonniaud (Dijon, France), J. Traclet (Lyon, France), K. Juvin (Paris, France), R. Borie (Paris, France), J. Bernaudin (Bobigny, France), D. Valeyre (Bobigny, France), C. Cavalin (Paris, France), H. Nunes (Bobigny, France)
Mapping IPF helps identify geographic regions at higher risk for disease development J. Shull (Barcelona, Spain), O. Jorba (Barcelona, Spain), C. Lara (Barcelona, Spain), M. Olid (Barcelona, Spain), M. Pay (Barcelona, Spain), G. Bermudo (Barcelona, Spain), G. Suarez Curatin (Barcelona, Spain), V. Vicens (Barcelona, Spain), L. Planas (Barcelona, Spain), J. Bordas (Barcelona, Spain), P. Rivera Ortega (Manchester, United Kingdom), M. Molina Molina (Barcelona, Spain), C. Group (Barcelona, Spain)
Primary results from the STARLINER study of disease behaviour in suspected ILD M. Wijsenbeek (Rotterdam, Netherlands), E. Bendstrup (Aarhus, Denmark), C. Valenzuela (Madrid, Spain), M. Henry (Cork, Ireland), C. Moor (Rotterdam, Netherlands), S. Jouneau (F-35000 Rennes, France), A. Fois (Sassari, Italy), O. Moran (Ontario, Canada), S. Anees (Windsor, Ontario, Canada), M. Mirt (Basel, Switzerland), M. Bengus (Basel, Switzerland), F. Gilberg (Basel, Switzerland), K. Kirchgaessler (Basel, Switzerland), C. Vancheri (Catania, Italy)
Clinical value of cluster analysis of unclassifiable idiopathic interstitial pneumonias phenotypes Y. Nakamura (Hamamatsu, Japan), T. Iwasawa (Yokohama, Japan), S. Matsushita (Kawasaki, Japan), Y. Terasaki (Tokyo, Japan), S. Kunugi (Tokyo, Japan), H. Kitamura (Yokohama, Japan), K. Mori (Hamamatsu, Japan), H. Yasui (Hamamatsu, Japan), T. Fujisawa (Hamamatsu, Japan), T. Suda (Hamamatsu, Japan)
The effect of metformin on clinically relevant outcomes in 3,144 IPF patients from the EMPIRE registry D. Jovanovic (Beograd, Republic of Serbia), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), K. Lewandowsk (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hájková (Bratislava, Slovakia), M. Kramer (Petah Tikva, Israel), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Studnicka (Salzburg, Austria), N. Stoeva (Sofia, Bulgaria), B. Jovovska Kaeva (Skopje), S. Littnerová (Brno, Czech Republic), M. Roksandic Milenkovic (Beograd, Republic of Serbia), M. Vasakova (Prague, Czech Republic)
Hiatus hernia and interstitial lung abnormalities P. George (London, United Kingdom), T. Hida (Boston, United States of America), R. Putman (Boston, United States of America), S. Desai (London, United Kingdom), A. Devaraj (London, United Kingdom), S. Kumar (London, United Kingdom), J. Mackintosh (Queensland, Australia), V. Gudnason (Reykjavik, Iceland), H. Hatabu (Boston, United States of America), G. Gudmundsson (Reykjavik, Iceland), G. Hunninghake (Boston, United States of America)
Effects of nintedanib in patients with IPF: subgroup analysis by Charlson Comorbidity Index (CCI) E. Bendstrup (Aarhus, Denmark), F. Bonella (Essen, Germany), E. Bargagli (Siena, Italy), F. Caro (Buenos Aires, Argentina), M. Glassberg (Miami, FL, United States of America), B. Schinzel (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), L. Orsatti (Ingelheim am Rhein, Germany), I. Glaspole (Melbourne, Victoria, Australia)
Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis P. Bonniaud (Dijon, France), V. Cottin (Lyon, France), P. Spagnolo (Padova, Italy), M. Nolin (Lyon, France), F. Dalon (Lyon, France), K. Kirchgässler (Basel, Switzerland), J. Chia (South San Francisco, United States of America), T. Kamath (South San Francisco, United States of America), E. Van Ganse (Lyon, France), M. Belhassen (Lyon, France)
Instant on site pathology of cryobiopsies in interstitial lung disease K. Mooij - Kalverda (Amsterdam, Netherlands), L. Van Huizen (Amsterdam, Netherlands), T. Radonic (Amsterdam, Netherlands), P. Bonta (Amsterdam, Netherlands), M. Groot (Amsterdam, Netherlands), J. Annema (Amsterdam, Netherlands)
Should we perform surgical lung biopsy when transbronchial cryobiopsy provides unclassifiable interstitial pneumonitis in a patient with diffuse interstitial lung disease? M. Asadi Gharabaghi (Tehran, Islamic Republic of Iran), E. Idani (Tehran, Islamic Republic of Iran), F. Mohammadi (Tehran, Islamic Republic of Iran), S. Izadi (Tehran, Islamic Republic of Iran), B. Boroofeh (Tehran, Islamic Republic of Iran), A. Maboudi (Tehran, Islamic Republic of Iran), B. Jahanbin (Tehran, Islamic Republic of Iran), S. Defaee (Tehran, Islamic Republic of Iran), N. Eftekhar (Tehran, Islamic Republic of Iran)
Precapillary pulmonary hypertension in patients with a high HFpEF probability: Insights from the Amsterdam UMC PAH-cohort A. Kianzad (Amsterdam, Netherlands), F. De Man (Amsterdam, Netherlands), L. Celant (Amsterdam, Netherlands), A. Vonk Noordegraaf (Amsterdam, Netherlands), L. Handoko (Amsterdam, Netherlands), H. Bogaard (Amsterdam, Netherlands)
Pulmonary abnormalities in newly diagnosed rheumatoid arthritis C. Hyldgaard (Silkeborg, Denmark), J. Blegvad (Silkeborg, Denmark), M. Herly (Odense, Denmark), D. Masic (Silkeborg, Denmark), B. Løgstrup (Aarhus, Denmark), B. Khaliqi (Odense, Denmark), G. Urbonaviciene (Silkeborg, Denmark), F. Andersen (Silkeborg, Denmark), C. Isaksen (Silkeborg, Denmark), B. Almasi (Silkeborg, Denmark), T. Ellingsen (Odense, Denmark)
Transbronchial lung cryobiopsy may be of value for nonresolving acute respiratory distress syndrome: case series and systematic literature review G. Zhou (Beijing, China), S. Wang (Beijing, China), Y. Feng (Beijing, China), Q. Zhan (Beijing, China), J. Geng (Beijing, China)
Late Breaking Abstract - Radial endobronchial ultrasound guided transbronchial cryobiopsy with fluoroscopy in the diagnosis of peripheral pulmonary nodule: first experience in the Hospital of LUHS Kauno klinikos V. Ankudavicius (Kaunas, Lithuania), M. Zemaitis (Kaunas, Lithuania), S. Miliauskas (Kaunas, Lithuania)
Serum markers of acute sarcoidosis. V. Evstifeev (Moscow, Russian Federation), E. Adamovskaya (Moscow, Russian Federation), G. Shepelkova (Moscow, Russian Federation), A. Zaytseva (Moscow, Russian Federation), E. Shmelev (Moscow, Russian Federation), V. Yeremeev (Moscow, Russian Federation)
Markers of resistance to corticosteroids therapy in patients with pulmonary sarcoidosis K. Shvets (Ivano-Frankivsk, Ukraine), M. Ostrovskyy (Ivano-Frankivsk, Ukraine), I. Savelikhina (Ivano-Frankivsk, Ukraine), O. Varunkiv (Ivano-Frankivsk, Ukraine), G. Korzh (Ivano-Frankivsk, Ukraine), K. Ostrovska (Ivano-Frankivsk, Ukraine)
Analysis of CD4 lymphocyte profiles in sarcoidosis and idiopathic pulmonary fibrosis D. Jiang (Beijing, China), H. Zhang (Beijing, China), H. Dai (Beijing, China), G. Zhou (Beijing, China), Y. Ren (Beijing, China), J. Geng (Beijing, China), B. Xie (Beijing, China)
Flow cytometric analysis of T cells maturation markers in mediastinal lymph nodes in sarcoidosis. E. Rutkowska (Warsaw, Poland), I. Kwiecien (Warsaw, Poland), J. Bednarek (Warsaw, Poland), R. Sokolowski (Warsaw, Poland), K. Jahnz-Rózyk (Warsaw, Poland), P. Rzepecki (Warsaw, Poland)
Morphological features in different course of sarcoidosis, forecast opportunity. O. Denisova (Tomsk, Russian Federation), I. Palchikova (Tomsk, Russian Federation), G. Chernjavskaya (Tomsk, Russian Federation), I. Purlik (Tomsk, Russian Federation), T. Kalacheva (Tomsk, Russian Federation), G. Chernogoryuk (Tomsk, Russian Federation), N. Shefer (Tomsk, Russian Federation)
Comparison among BAL biomarkers in ILD discrimination and course prediction G. Paone (Roma (RM), Italy), G. De Rose (Roma (RM), Italy), D. Pellegrino (Roma (RM), Italy), G. Lucantoni (Roma (RM), Italy), I. Cuccaro (Roma (RM), Italy), I. Menichini (Roma (RM), Italy), G. Leodori (Roma (RM), Italy), C. Pellicano (Roma (RM), Italy), A. Sebastiani (Roma (RM), Italy), E. Rosato (Roma (RM), Italy), P. Palange (Roma (RM), Italy)
The role of TREM-1 and TREM-2 receptors in immunopathogenesis of pulmonary sarcoidosis and hypersensitivity pneumonitis E. Tedlova (Bratislava, Slovakia), M. Suchankova (Bratislava, Slovakia), J. Urban (Vysne Hagy, Slovakia), M. Ganovska (Vysne Hagy, Slovakia), E. Tibenska (Bratislava, Slovakia), K. Szaboova (Bratislava, Slovakia), I. Majer (Bratislava, Slovakia), M. Bobovcak (Bratislava, Slovakia), I. Jonner (Vysne Hagy, Slovakia), M. Bucova (Bratislava, Slovakia)
Increased fraction of small round lymphocyte in BALF is a diagnostic indicator for sarcoidosis Y. Horimasu (Hiroshima, Japan), K. Yamaguchi (Hiroshima, Japan), S. Sakamoto (Hiroshima, Japan), T. Masuda (Hiroshima, Japan), S. Miyamoto (Hiroshima, Japan), T. Nakashima (Hiroshima, Japan), H. Iwamoto (Hiroshima, Japan), S. Ohshimo (Hiroshima, Japan), K. Fujitaka (Hiroshima, Japan), H. Hamada (Hiroshima, Japan), N. Hattori (Hiroshima, Japan)
Increased monocyte count and red cell distribution width represent negative prognostic markers in patients with Hypersensitivity Pneumonitis T. Karampitsakos (Athens, Greece), E. Bouros (Athens, Greece), O. Papaioannou (Athens, Greece), S. Tsipilis (Athens, Greece), C. Antonou (Athens, Greece), M. Ntassiou (Athens, Greece), S. Chrysikos (Athens, Greece), A. Anagnostopoulos (Athens, Greece), K. Cholidou (Athens, Greece), E. Koukaki (Athens, Greece), M. Katsaras (Athens, Greece), V. Tzilas (Athens, Greece), K. Dimakou (Athens, Greece), D. Bouros (Athens, Greece), A. Tzouvelekis (Athens, Greece)
Association of HLA variants with sarcoidosis in Korean population: pilot study M. Petrek (Olomouc, Czech Republic), K. Sikorová (Olomouc, Czech Republic), M. Kim (Seoul, Republic of Korea), V. Žižková (Olomouc, Czech Republic), S. Moon (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea)
Homozygous mutations of ARFGAP1 gene in severe sarcoidosis T. EL JAMMAL (Lyon, France), A. Calender (Lyon, France), P. Sève (Lyon, France), Y. Pachéco (Lyon, France)
Sarcopenia in idiopathic pulmonary fibrosis (IPF): Prevalence and response to pulmonary rehabilitation (PR) C. Nolan (London, United Kingdom), M. Maddocks (London, United Kingdom), T. Maher (London, United Kingdom), S. Patel (London, United Kingdom), R. Barker (London, United Kingdom), J. Walsh (London, United Kingdom), O. Polgar (London, United Kingdom), P. George (London, United Kingdom), W. Man (London, United Kingdom)
Evaluation of dissemination activity in pulmonary diseases R. Amansahedov (Moscow, Russian Federation), L. Dmitrieva (Moscow, Russian Federation), N. Karpina (Moscow, Russian Federation), L. Lepekha (Moscow, Russian Federation), R. Kazho (Moscow, Russian Federation), A. Sigaev (Moscow, Russian Federation), A. Borisova (Moscow, Russian Federation), A. Ergeshov (Moscow, Russian Federation)
Analysis of the ratio of the main pulmonary artery to that of the aorta on chest CT in patients with combined pulmonary fibrosis and emphysema. T. Hirouchi (Tokyo, Japan), S. Ota (Tokyo, Japan), M. Nishimura (Tokyo, Japan), K. Shinada (Tokyo, Japan), M. Morikawa (Tokyo, Japan), S. Yamanaka (Tokyo, Japan), M. Shinoda (Tokyo, Japan), O. Sasaki (Tokyo, Japan), M. Shinkai (Tokyo, Japan)
Cytokines, chemokines and growth factors concentration in BAL fluid from patients with Idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) M. Kaestle (Biberach an der Riß, Germany), K. Geillinger-Kästle (Biberach an der Riß, Germany), D. Lamb (Biberach an der Riß, Germany), U. Costabel (Essen, Germany), D. Theegarten (Essen, Germany), S. Uddin (Biberach an der Riß, Germany), M. Thomas (Biberach an der Riß, Germany), L. Wollin (Biberach an der Riß, Germany), F. Bonella (Essen, Germany)
Impact of BAL lymphocytosis > 15% on the prognosis of chronic idiopathic interstitial pneumonias other than idiopathic pulmonary fibrosis: a retrospective nationwide study based on multidisciplinary discussion A. Yamagata (Okayama, Japan), M. Arita (Okayama, Japan), F. Tokioka (Okayama, Japan), C. Sugimoto (Osaka, Japan), H. Sumikawa (Osaka, Japan), T. Tanaka (Hyogo, Japan), H. Yasui (Shizuoka, Japan), T. Fujisawa (Shizuoka, Japan), Y. Nakamura (Shizuoka, Japan), T. Suda (Shizuoka, Japan), T. Ishida (Okayama, Japan)
Neutrophil-to-lymphocyte ratio in IPF patients: a novel prognostic biomarker? . d'Alessandro (Siena, Italy), L. Bergantini (Siena, Italy), P. Cameli (Siena, Italy), A. Carleo (Hannover, Germany), P. Sestini (Siena, Italy), E. Bargagli (Siena, Italy)
Serum ST2 in Idiopathic Pulmonary Fibrosis (IPF): a possible new biomarker of disease? F. Cavalli (Roma (RM), Italy), E. Puxeddu (Roma (RM), Italy), G. Cillis (Roma (RM), Italy), E. Teodori (Roma (RM), Italy), M. Perrone (Roma (RM), Italy), P. Rogliani (Roma (RM), Italy)
Endotrophin is related to disease progression in idiopathic pulmonary fibrosis H. Jessen (Herlev, Denmark), N. Hoyer (Copenhagen, Denmark), S. Rønnow (Herlev, Denmark), M. Karsdal (Herlev, Denmark), D. Leeming (Herlev, Denmark), J. Sand (Herlev, Denmark), S. Shaker (Copenhagen, Denmark)
KL-6 as a potential therapeutic biomarker in fibrosing interstitial lung diseases V. Somogyi (Heidelberg, Germany), K. Mayer (Heidelberg, Germany), K. Kriegsmann (Heidelberg, Germany), M. Kriegsmann (Heidelberg, Germany), P. Findeisen (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany)
IL-18 binding protein as a noble biomarker for idiopathic pulmonary fibrosis Y. Nakanisihi (Hiroshima, Japan), Y. Horimasu (Hiroshima, Japan), K. Yamaguchi (Hiroshima, Japan), S. Sakamoto (Hiroshima, Japan), T. Masuda (Hiroshima, Japan), T. Nakashima (Hiroshima, Japan), S. Miyamoto (Hiroshima, Japan), H. Iwamoto (Hiroshima, Japan), K. Fujitaka (Hiroshima, Japan), H. Hamada (Hiroshima, Japan), N. Hattori (Hiroshima, Japan)
Methylprednisolone pulse therapy in Acute Exacerbations of Idiopathic Pulmonary Fibrosis P. Mari (Roma (RM), Italy), M. Siciliano (Roma (RM), Italy), F. Cefaloni (Roma (RM), Italy), S. Cortese (Roma (RM), Italy), E. Schiavi (Roma (RM), Italy), B. Iovene (Roma (RM), Italy), G. Sgalla (Roma (RM), Italy), G. Corbo (Roma (RM), Italy), F. Varone (Roma (RM), Italy), L. Richeldi (Roma (RM), Italy)
Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease T. Furukawa (Nagoya (Aichi), Japan), S. Oyama (Nagoya (Aichi), Japan), H. Yokota (Wako, Japan), Y. Kondoh (Seto, Japan), Y. Shiratori (Nagoya (Aichi), Japan), Y. Hasegawa (Nagoya (Aichi), Japan)
A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients N. LE-DONG (Erpent, Belgium), T. Hua-Huy (Paris, France), T. Hoang-Thi (Paris, France), V. Codullo (Paris, France), Y. Allanore (Paris, France), A. Dinh-Xuan (Paris, France)
Antisynthetase syndrome related interstitial lung disease may have a better treatment response than other forms of Idiopathic Inflammatory Myopathies: a multi-national study J. Enghelmayer (Buenos Aires, Argentina), F. Vivero (Mar del Plata, Argentina), S. Leiva Aguero (La Rioja, Argentina), S. Quadrelli (Buenos Aires, Argentina), D. Lancelloti (Mar del Plata, Argentina), F. Campins (Mar del Plata, Argentina), J. Sebastiani (Mar del Plata, Argentina), P. Malfante (Mar del Plata, Argentina), E. Gandara (Mar del Plata, Argentina), V. Basso (Mar del Plata, Argentina), M. Romiti (Mar del Plata, Argentina), A. Gaser (Buenos Aires, Argentina), M. Sacnun (Rosario, Argentina), F. Zenon (Buenos Aires, Argentina), R. Gomez (Buenos Aires, Argentina), P. Aruj (Buenos Aires, Argentina), F. Pacello (Paysandu, Uruguay), N. Naval (Tucuman, Argentina), V. Moyano (Cordoba, Argentina), J. Maritano (Buenos Aires, Argentina), M. Alberti (Buenos Aires, Argentina), F. Paulin (Buenos Aires, Argentina), M. Usandivaras (Tucuman, Argentina), S. Auteri (Rosario, Argentina), C. Isnardi (Buenos Aires, Argentina), G. Tabaj (Buenos Aires, Argentina), B. Varela (Buenos Aires, Argentina), F. Caro (Buenos Aires, Argentina), S. Altube (Buenos Aires, Argentina), M. Lagrutta (Rosario, Argentina), J. Abdala (Mendoza, Argentina), C. Lilian (Buenos Aires, Argentina), L. Molinari (Rio Negro, Argentina), B. Gil (Tucuman, Argentina), M. Otaola (Buenos Aires, Argentina)
Prevalence and mortality of systemic sclerosis-associated interstitial lung disease (SSc-ILD) using the French national health insurance system (SNDS) database in France M. Nasser (Lyon, France), S. Larrieu (Bordeaux, France), L. Boussel (Lyon, France), S. Si-Mohamed (Lyon, France), F. Bazin (Bordeaux, France), S. Marque (Bordeaux, France), J. Massol (Paris, France), D. Revel (Lyon, France), F. Thivolet-Bejui (Lyon, France), L. Chalabreysse (Lyon, France), D. Maucort-Boulch (Lyon, France), E. Hachulla (Lyon, France), S. Jouneau (Lyon, France), V. Cottin (Lyon, France)
Rheumatoid arthritis associated interstitial lung disease in KwaZulu-Natal, South Africa: Clinical profile and treatment outcomes M. Mitha (Durban (Kwa Zulu-Natal), South Africa), H. Ghammo (Durban (Kwa Zulu-Natal), South Africa), C. Connolly (Durban (Kwa Zulu-Natal), South Africa), K. Nyamande (Durban (Kwa Zulu-Natal), South Africa)
Does “UIPAF” really exist? G. Sambataro (CATANIA, Italy), A. Libra (CATANIA, Italy), S. Puglisi (FORLI', Italy), M. Pavone (CATANIALI', Italy), F. Pino (CATANIALI', Italy), S. Torrisi (CATANIALI', Italy), G. Sardo (CATANIALI', Italy), A. Vancheri (CATANIALI', Italy), S. Palmucci (CATANIALI', Italy), S. Tomassetti (FORLI', Italy), V. Poletti (AAHRUS, Denmark), C. Vancheri (CATANIA, Italy)
Fibrosis score predicts mortality in patients with chronic hypersensitivity pneumonitis J. Kang (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea)